CAMP4 Therapeutics Corporation
CAMP · NASDAQ
12/31/2024 | 12/31/2023 | 11/30/2023 | 2/28/2023 | |
|---|---|---|---|---|
| Revenue | $652 | – | $350 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | – | $0 | $0 |
| Gross Profit | $652 | – | $350 | $0 |
| % Margin | 100% | – | 100% | – |
| R&D Expenses | $38,817 | – | $40,616 | $34,771 |
| G&A Expenses | $14,923 | – | $11,613 | $10,230 |
| SG&A Expenses | $14,923 | – | $11,613 | $10,230 |
| Sales & Mktg Exp. | $0 | – | $0 | $0 |
| Other Operating Expenses | $0 | – | $0 | $0 |
| Operating Expenses | $53,740 | – | $52,229 | $45,001 |
| Operating Income | -$53,088 | – | -$51,879 | -$45,001 |
| % Margin | -8,142.3% | – | -14,822.6% | – |
| Other Income/Exp. Net | $1,297 | – | $2,588 | $809 |
| Pre-Tax Income | -$51,791 | – | -$49,291 | -$44,192 |
| Tax Expense | $0 | – | $0 | $0 |
| Net Income | -$51,791 | – | -$49,291 | -$44,192 |
| % Margin | -7,943.4% | – | -14,083.1% | – |
| EPS | -2.66 | – | -4.07 | -0.9 |
| % Growth | – | – | -352.2% | – |
| EPS Diluted | -2.66 | – | -4.07 | -0.9 |
| Weighted Avg Shares Out | 19,505 | – | 12,125 | 36,100 |
| Weighted Avg Shares Out Dil | 19,505 | – | 12,125 | 36,132 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1,330 | – | $2,808 | $0 |
| Interest Expense | $0 | – | $0 | $6,260 |
| Depreciation & Amortization | $1,696 | – | $1,678 | $878 |
| EBITDA | -$51,392 | – | -$50,201 | -$44,123 |
| % Margin | -7,882.2% | – | -14,343.1% | – |